METHODS OF MEDICAL TREATMENT WITH SUR1-TRPM4 CHANNEL INHIBITORS
A method of treating or preventing adverse outcomes associated with tissue plasminogen activator (tPA) administration, cerebral edema-related side effects, cerebral edema associated with radiation therapy, or migraine headaches by administering an effective amount of a SUR1-TRPM4 channel inhibitor, such as glyburide, and optionally the co-administration of a second therapeutically active agent, to a subject in need thereof. Adverse outcomes associated with tPA include cerebral hemorrhage, cerebral edema, physical impairment or death. The administration of the SUR1-TRPM4 channel inhibitors occurs prior to the radiation therapy, during the radiation therapy, after the radiation therapy, or combinations thereof. The SUR1-TRPM4 channel inhibitor is administered prior to surgical excision of a brain tumor, CAR-T therapy, or administration of flutarabine. Alternatively, or in addition, the SUR1-TRPM4 channel inhibitor is administered prior the onset of the cerebral edema-related side effects.
1 . A method of treating or preventing one or more adverse outcomes associated with tissue plasminogen activator (tPA) administration, comprising administering an effective amount of a SUR1-TRPM4 channel inhibitor to a subject in need of tPA administration.
2 . The method of claim 1 , wherein the SUR1-TRPM4 channel inhibitor comprises at least one of glyburide, 4-trans-hydroxy-glibenclamide, 3-cis-hydroxyglibenclamide, tolbutamide, chlorpropamide, repaglinide, nateglinide, meglitinide, midaglizole, tolazamide, gliquidone, LY397364, LY389382, glyclazide, glimepiride, 9-phenantrol, fluflenamic acid, riluzole, spermine, adenosine, quinine, quinidine, diphenylamine-2-carboxylic acid, 3′,5′-dichlorodiphenylamine-2-carboxylic acid, 5-nitro-2-(3-phenylpropyl-amino)-benzoic acid, MPB-104, or a combination thereof.
3 . The method of claim 1 , wherein the SUR 1 -TRPM 4 channel inhibitor comprises glyburide.
4 . The method of claim 1 , wherein the one or more adverse outcomes comprises at least one of cerebral hemorrhage, cerebral edema, or physical impairment.
5 . The method of claim 1 , wherein the subject has an Alberta Stroke Program Early CT Score (ASPECTS) that is equal to or less than 7.
6 . The method of claim 1 , comprising administering the SUR1-TRPM4 channel inhibitor for about 1 hour to about 96 hours.
7 . The method of claim 1 , comprising administering at least a portion of the SUR1-TRPM4 channel inhibitor prior to the administration of tPA.
8 . The method of claim 1 , comprising administering at least a portion of the SUR1-TRPM4 channel inhibitor simultaneously with the tPA.
9 . The method of claim 1 , comprising administering at least a portion of the SUR1-TRPM4 channel inhibitor after the administration of tPA.
10 . The method of claim 1 , comprising administering the SUR1-TRPM4 channel inhibitor via one or more continuous infusions.
11 . The method of claim 1 , comprising administering the SUR1-TRPM4 channel inhibitor via injection.
12 . The method of claim 1 , comprising administering the SUR1-TRPM4 channel inhibitor via a transdermal patch or gel.
13 . The method of claim 1 , comprising administering the SUR1-TRPM4 inhibitor orally.
14 . The method of claim 1 , comprising administering the SUR1-TRPM4 channel inhibitor at a dosage of 0.05 mg/day to 3.0 mg/day.
15 . The method of claim 1 , comprising administering the SUR1-TRPM4 channel inhibitor in an amount sufficient to effect a SUR1-TRPM4 channel inhibitor plasma level of 0.4 ng/mL to 5 ng/mL in said patient.
16 . The method of claim 1 , comprising administering the SUR1-TRPM4 channel inhibitor in an amount sufficient to effect a steady-state SUR1-TRPM4 channel inhibitor concentration of 3.0 ng/mL to 30.0 ng/ml in the patient.
17 . The method of claim 1 , comprising administering the SUR1-TRPM4 channel inhibitor in an amount sufficient to effect a Cmax of the SUR1-TRPM4 channel inhibitor of 1 ng/ml to 30 ng/ml in the patient.
18 . The method of claim 1 , wherein the subject has experienced a large hemispheric infarction (LHI).
19 . The method of claim 1 , wherein the subject has a lesion volume of 80-300 mL.